5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Advanced Solid Tumors



Status:Archived
Conditions:Breast Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011

Use our guide to learn which trials are right for you!

A Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine in Advanced Malignancies


RATIONALE: Drugs used in chemotherapy, such as 5-fluoro-2'-deoxycytidine and
tetrahydrouridine, work in different ways to stop the growth of tumor cells, either by
killing the cells or by stopping them from dividing. Giving more than one drug (combination
chemotherapy) may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of
5-fluoro-2'-deoxycytidine when given together with tetrahydrouridine in treating patients
with advanced solid tumors.


OBJECTIVES:

- Determine the maximum tolerated dose of 5-fluoro-2'-deoxycytidine when given together
with tetrahydrouridine in patients with advanced solid tumors.

- Determine the toxicity of this regimen in these patients.

- Obtain preliminary evidence of antitumor activity of this regimen in these patients.

- Assess the pharmacokinetics of this regimen in these patients.

- Evaluate the oral bioavailability of this regimen in these patients.

- Determine the relative levels of mRNAs for thymidylate synthase, deoxycytidine kinase,
dCMP deaminase, and other relevant enzymes in patients treated with this regimen.

- Determine the methylation status of p16 and other genes relevant to neoplasias.

OUTLINE: This is a multicenter, dose-escalation study of 5-fluoro-2'-deoxycytidine (5FD).

Patients receive a single dose of oral tetrahydrouridine (THU) and oral 5FD on day 1
followed by THU IV over 3 hours and 5FD IV over 3 hours on days 2-5 and 8-12* in course 1.
Beginning in course 2 and all subsequent courses, patients receive THU IV over 3 hours and
5FD IV over 3 hours on days 1-5 and 8-12. Treatment repeats every 28 days in the absence of
unacceptable toxicity or disease progression.

NOTE: *Patients receive 5FD orally on day 8 and then IV over 3 hours on days 9-12 of course
1.

Cohorts of 3-6 patients receive escalating doses of 5FD until the maximum tolerated dose
(MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6
patients experience dose-limiting toxicity.

Blood and biopsy samples are collected at baseline and periodically during study for
pharmacodynamic studies. Plasma and urine samples are collected periodically during study
for pharmacokinetic studies.

PROJECTED ACCRUAL: A total of 80 patients will be accrued for this study.


We found this trial at
4
sites
1500 E Duarte Rd
Duarte, California 91010
(626) 256-4673
City of Hope Comprehensive Cancer Center City of Hope is a leading research and treatment...
?
mi
from
Duarte, CA
Click here to add this to my saved trials
2279 45th Street
Sacramento, California 95817
(916) 734-5800
University of California Davis Cancer Center At UC Davis Comprehensive Cancer Center, specialized teams of...
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
9000 Rockville Pike
Bethesda, Maryland 20892
1-800-422-6237
National Cancer Institute (NCI) The National Cancer Institute (NCI) is part of the National Institutes...
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
Los Angeles, California 90089
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials